dc.contributor.author |
Simó Canonge, Rafael |
dc.contributor.author |
Bañeras, Jordi |
dc.contributor.author |
Hernández, Cristina |
dc.contributor.author |
Rodríguez-Palomares, José |
dc.contributor.author |
Valente, Filipa |
dc.contributor.author |
Gutierrez, Laura |
dc.contributor.author |
González-Alujas, Teresa |
dc.contributor.author |
Ferreira-Gonzalez, Ignacio |
dc.contributor.author |
Aguadé-Bruix, Santiago |
dc.contributor.author |
Montaner, Joan |
dc.contributor.author |
Seron, Daniel |
dc.contributor.author |
Genescà Ferrer, Joan |
dc.contributor.author |
Boixadera Espax, Anna |
dc.contributor.author |
García Arumí, José |
dc.contributor.author |
Planas, Alejandra |
dc.contributor.author |
Simó-Servat, Olga |
dc.contributor.author |
García-Dorado, David |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2019 |
dc.identifier |
https://ddd.uab.cat/record/223269 |
dc.identifier |
urn:10.1136/bmjdrc-2019-000845 |
dc.identifier |
urn:oai:ddd.uab.cat:223269 |
dc.identifier |
urn:scopus_id:85077370630 |
dc.identifier |
urn:articleid:20524897v7n1e000845 |
dc.identifier |
urn:pmid:31908800 |
dc.identifier |
urn:pmc-uid:6936469 |
dc.identifier |
urn:pmcid:PMC6936469 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:6936469 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Instituto de Salud Carlos III PIE 2013/27 |
dc.relation |
Instituto de Salud Carlos III RD16/0019/0021 |
dc.relation |
BMJ open diabetes research and care ; Vol. 7 Núm. 1 (29 2019), p. e000845 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by-nc/4.0/ |
dc.title |
Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease : Baseline results of the PRECISED study |
dc.type |
Article |
dc.description.abstract |
Funding This work was supported by an Integrative Excellence Project by the Spanish Institute of Health, Instituto de Salud Carlos III, grant PIE 2013/27, CIBER CV, CIBERDEM, and the European Regional Development Fund (ERDF-FEDER). The Neurovascular Research Laboratory is part of the Spanish Stroke Research Network INVICTUS+ (RD16/0019/0021). |
dc.description.abstract |
Objective Detection of subclinical cardiovascular disease (CVD) has significant impact on the management of type 2 diabetes. We examined whether the assessment of diabetic retinopathy (DR) is useful for identifying patients at a higher risk of having silent CVD. Research design and methods Prospective case-control study comprising 200 type 2 diabetic subjects without history of clinical CVD and 60 age-matched non-diabetic subjects. The presence of subclinical CVD was examined using two parameters: (1) calcium coronary score (CACs); (2) composite of CACs >400 UA, carotid plaque ≥3 mm, carotid intima-media thickness ratio >1, or the presence of ECG changes suggestive of previous asymptomatic myocardial infarction. In addition, coronary angio-CT was performed. DR was assessed by slit-lamp biomicroscopy and retinography. Results Type 2 diabetic subjects presented higher CACs than non-diabetic control subjects (p<0.01). Age, male gender, and the presence of DR were independently related to CACs >400 (area under the receiver operating characteristic curve (AUROC) 0.76). In addition, an inverse relationship was observed between the degree of DR and CACs <10 AU. The variables independently associated with the composite measurement of subclinical CVD were age, diabetes duration, the glomerular filtration rate, microalbuminuria, and the presence of DR (AUROC 0.71). In addition, a relationship (p<0.01) was observed between the presence and degree of DR and coronary stenosis. Conclusions The presence and degree of DR is independently associated with subclinical CVD in type 2 diabetic patients. Our results lead us to propose a rationalized screening for coronary artery disease in type 2 diabetes based on prioritizing patients with DR, particularly those with moderate-severe degree. |